Dr. Shen directs their formulation design and drug discovery effort. He has more than 20 years of drug discovery experience, including formulation studies, medicinal chemistry, and technology transfer, contract manufacturing and scale-up. Dr. Shen has extensive experience in pharmaceutical analysis, method development and validation, stability studies, development of product specifications. He has supported Chemistry, Manufacturing and Controls (CMC) efforts for numerous IND submissions. Dr. Shen held various leadership positions at Abbott Laboratories, Sunesis Pharmaceuticals and Amgen before co-founding Kanion USA in 2009. He has led and co-led discovery of multiple clinical programs, including lifitegrast (NDA filed in 2014) and early discovery of ABT-199 (in Phase 3). Dr. Shen has authored and co-authored over 40 publications in peer-reviewed journals, and an inventor on over 50 issued patents and applications. Dr. Shen received his Ph.D. degree in chemistry from University of Pittsburgh, and completed postdoctoral training at Sloan-Kettering Memorial Cancer Center in New York.